Overview
- Editors:
-
-
Keith L. March
-
Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, USA
R. L. Roudebush VA Medical Center, Indianapolis, USA
Access this book
Other ways to access
Table of contents (21 chapters)
-
Gene Delivery for Local Cardiac Expression
-
- Doris A. Taylor, Brian H. Annex, William E. Kraus, Sanford P. Bishop, Scott C. Silvestry
Pages 355-375
-
-
Gene Delivery for Systemic Expression
-
Front Matter
Pages 393-393
-
-
- Susan C. Stevenson, Alan McClelland
Pages 433-448
-
-
Biophysical Considerations in Vector Delivery
-
Front Matter
Pages 475-475
-
- Keith L. March, R. L. Roudebush, Bruce C. Trapnell
Pages 477-498
-
Back Matter
Pages 499-516
About this book
The goal of gene transfer is protein expression. a process brought about by the insertion of a gene coding for a foreign protein into target cells resulting in the synthesis of the foreign protein For gene therapy, a tmnsferred therapeutic gene must be expressed at a level beneficial for the patient. This chapter provides an introductory overview of the rapidly evolving field of non-viral approaches for gene delivery to rnarnrnalian cells. Although currently there are fewer ongoing clinical trials using non-viral approaches than those using viral based systems, the number of non-viral trials is increasing. The long range goal of some research groups is the development of a genetically engineered artificial virus targeted to specific cells in the human body. An arurual conference, organized by Cambridge Healthtech Institute entitled "Artificial Self-Assembling Systems for Gene Transfer", brings together researchers interested in this field [1]. Assembly of an artificial virus is very complex; other research groups aim to develop simpler delivery systems consisting of a plasmid combined with delivery agents. Viral-based systems are very successful for gene delivery, but despite their successes, viral-based systems have some geneml limitations and system-specific limitations. When employing a viml-based system, the following limitations should be considered: • size limitation of the inserted gene due to packaging constraints (e. g. adenovirus, retrovirus) . • potential tumorigenesis (e. g. retrovirus) • potential for insertional mutagenesis (greater than plasmid based systems) • potential imrnunogenicity (e. g.
Editors and Affiliations
-
Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, USA
Keith L. March
-
R. L. Roudebush VA Medical Center, Indianapolis, USA
Keith L. March
